Windtree Therapeutics is a clinical-stage, biopharmaceutical and medical device company focused on the development of therapeutics to address unmet medical needs in acute care markets. Co.'s primary cardiovascular product candidate, istaroxime, is a dual-acting agent being developed to improve cardiac function in patients with acute heart failure and cardiogenic shock. Co.'s primary pulmonary product candidate is AEROSURF® (lucinactant for inhalation), a drug/medical device combination for non-invasive delivery of its proprietary aerosolized KL4 surfactant, using its proprietary Aerosol Delivery System technology for the treatment of respiratory distress syndrome in premature infants. The WINT stock yearly return is shown above.
The yearly return on the WINT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the WINT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|